Transcription factor activity and inferred myeloid-CD8 signaling by pathological response in lung adenocarcinoma and squamous cell carcinoma after neoadjuvant PD-1 therapy
Patients with resectable non-small cell lung cancer differ widely in the depth of their pathological response to neoadjuvant anti-PD-1 plus chemotherapy, and what distinguishes tumors with a major pathological response (MPR) from those without is incompletely defined. We analyzed a published single-cell dataset of CD45+ cells from 234 patients. After excluding complete pathological responders, MPR and non-MPR tumors were compared separately in adenocarcinoma and squamous carcinoma. Exhausted CD8 T cells (CD8.TEX) and tumor-associated macrophages (TAMs) were characterized by composition and functional state, transcription factor activity, and cell-cell communication. In CD8.TEX cells, cytotoxicity and exhaustion scores were significantly higher in non-MPR tumors in both histologies. The proportion of CD8.TEX cells was significantly higher in non-MPR tumors in squamous carcinoma but not in adenocarcinoma. Transcription factor activity differed significantly in adenocarcinoma (12 of 479 factors, 10 more active in non-MPR tumors and 2 in MPR tumors) but none of the 461 factors tested in squamous carcinoma did. In squamous carcinoma, 258 genes were differentially expressed in CD8.TEX cells, and 145 of them (56%) have no documented regulator in the network used (24 of 65, 37%, in adenocarcinoma). In the myeloid compartment, the proportions of macrophages and monocytes did not differ significantly between response groups, whereas transcription factor activity did, mostly higher in non-MPR tumors (adenocarcinoma: 68 of 70 factors in macrophages and 35 of 36 in monocytes; squamous carcinoma: 7 of 8 and 9 of 13). Nine ligand-receptor axes described in the literature (four immunosuppressive, two anti-tumor and three context-dependent) were found among the interactions prioritized for CD8.TEX cells. In non-MPR tumors, all nine were found in adenocarcinoma and eight in squamous carcinoma, against one and two, respectively, in MPR tumors. In this cohort, the differences between MPR and non-MPR tumors lay mostly on the non-MPR side, both in transcription factor activity and in the literature axes found among the prioritized interactions.
Authors
- Myriam Yasmina Soumahoro (ORCID: https://orcid.org/0009-0009-8549-5340)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24423379
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- preprint